Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Kala Pharmaceuticals Inc (KALA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 214,292
  • Shares Outstanding, K 33,800
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,210 K
  • 36-Month Beta 0.63
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.55
  • Number of Estimates 4
  • High Estimate -0.49
  • Low Estimate -0.60
  • Prior Year -0.46
  • Growth Rate Est. (year over year) -19.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.13 +3.43%
on 11/14/18
10.21 -37.90%
on 10/16/18
-2.22 (-25.93%)
since 10/12/18
3-Month
6.13 +3.43%
on 11/14/18
14.45 -56.12%
on 08/22/18
-5.58 (-46.81%)
since 08/14/18
52-Week
6.13 +3.43%
on 11/14/18
22.10 -71.31%
on 11/24/17
-13.73 (-68.41%)
since 11/14/17

Most Recent Stories

More News
Kala Pharmaceuticals Reports Third Quarter 2018 Financial Results

--- Strengthened Cash Position; Runway Extends At Least Through Early 2020 -

KALA : 6.34 (-3.35%)
Will Cigna (CI) Q3 Earnings Gain on Revenue Growth?

Cigna (CI) Q3 earnings should gain from revenue and membership growth

CI : 212.35 (-0.33%)
ANTM : 280.10 (-0.05%)
KALA : 6.34 (-3.35%)
AMAG : 17.04 (-1.22%)
Kala Pharmaceuticals Appoints Steven Zhang as Vice President of Medical Affairs

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY(TM) mucus-penetrating...

KALA : 6.34 (-3.35%)
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2017 Equity Incentive...

KALA : 6.34 (-3.35%)
Kala Pharmaceuticals to Present at the 2018 American Academy of Ophthalmology (AAO) Annual Meeting and at the Ophthalmology Innovation Summit at AAO

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that it will present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology (OIS@AAO) meeting taking...

KALA : 6.34 (-3.35%)
Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for KPI-121 0.25% for Dry Eye Disease

Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for KPI-121 0.25%,...

KALA : 6.34 (-3.35%)
Kala Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

Kala Pharmaceuticals, Inc. ("Kala") (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle...

JPM : 107.33 (-2.06%)
KALA : 6.34 (-3.35%)
Kala Pharmaceuticals (KALA) Catches Eye: Stock Jumps 7.4%

Kala Pharmaceuticals (KALA) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

KALA : 6.34 (-3.35%)
AMGN : 190.36 (-0.62%)
Kala Pharmaceuticals Announces Pricing of Public Offering of 7,500,000 Shares of Common Stock

Kala Pharmaceuticals, Inc. ("Kala") (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle...

JPM : 107.33 (-2.06%)
KALA : 6.34 (-3.35%)
Kala Pharmaceuticals Announces Proposed Public Offering of Common Stock

Kala Pharmaceuticals, Inc. ("Kala") (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle...

JPM : 107.33 (-2.06%)
KALA : 6.34 (-3.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade KALA with:

Business Summary

Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles technology. The Company designs proprietary drug delivery technology to penetrate mucosal tissue such as the eyes,...

See More

Key Turning Points

2nd Resistance Point 7.01
1st Resistance Point 6.68
Last Price 6.34
1st Support Level 6.07
2nd Support Level 5.79

See More

52-Week High 22.10
Fibonacci 61.8% 16.00
Fibonacci 50% 14.11
Fibonacci 38.2% 12.23
Last Price 6.34
52-Week Low 6.13

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar